However, to exploit ETV4 as a therapeutic target would demand a deep biochemical understanding of ETV4 and its interactions with other proteins, and of the mechanisms underlying its aberrant expression in PC (Figure 1). This evidence concerns the gene ETV4 and pachyonychia congenita.